-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 GnIB8tubZUi0VyvlPhhNIuWJ9DgvFp47VeDkMlkE2c0UhjlfPPsA8UBMnTg2SmDZ
 MmV3qIQMjHao585DvEk7eA==

<SEC-DOCUMENT>0000950123-11-004606.txt : 20110124
<SEC-HEADER>0000950123-11-004606.hdr.sgml : 20110124
<ACCEPTANCE-DATETIME>20110121210406
ACCESSION NUMBER:		0000950123-11-004606
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20110119
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20110124
DATE AS OF CHANGE:		20110121

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Lifevantage Corp
		CENTRAL INDEX KEY:			0000849146
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				841097796
		STATE OF INCORPORATION:			CO
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30489
		FILM NUMBER:		11542458

	BUSINESS ADDRESS:	
		STREET 1:		11545 WEST BERNARDO COURT
		STREET 2:		SUITE 301
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92127
		BUSINESS PHONE:		858-312-8000

	MAIL ADDRESS:	
		STREET 1:		11545 WEST BERNARDO COURT
		STREET 2:		SUITE 301
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92127

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	LIFELINE THERAPEUTICS, INC.
		DATE OF NAME CHANGE:	20041019

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	YAAK RIVER RESOURCES INC
		DATE OF NAME CHANGE:	19920703

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ANDRAPLEX CORP
		DATE OF NAME CHANGE:	19920406
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>a58426e8vk.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
<TITLE>e8vk</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 1pt solid black; font-size: 1pt">&nbsp;</DIV>




<DIV align="center" style="font-size: 14pt; margin-top: 12pt"><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION</B>
</DIV>

<DIV align="center" style="font-size: 12pt"><B>Washington, D.C. 20549</B>
</DIV>

<DIV align="center" style="font-size: 18pt; margin-top: 12pt"><B>FORM 8-K</B>
</DIV>


<DIV align="center" style="font-size: 12pt; margin-top: 12pt"><B>CURRENT REPORT<BR>
Pursuant to Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><!-- xbrl,dc --><B>Date of Report (Date of earliest event reported): January&nbsp;19, 2011</B><!-- /xbrl,dc --></DIV>

<DIV align="center" style="font-size: 24pt; margin-top: 12pt"><B>Lifevantage Corporation</B>
</DIV>

<DIV align="center" style="font-size: 10pt">(Exact name of registrant as specified in its charter)</DIV>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="31%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="31%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="31%">&nbsp;</TD>
</TR>
<TR></TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top"><B>Colorado</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>000-30489</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>90-0224471</B></TD>
</TR>
<TR style="font-size: 1px">
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top">(State or other Jurisdiction of
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">(Commission File Number)
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">(IRS Employer Identification</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top">Incorporation)
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">No.)</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="47%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="47%">&nbsp;</TD>
</TR>
<TR></TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top"><B>11545 W. Bernardo Court, Suite&nbsp;301, San Diego,</B></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><B>California</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>92127</B></TD>
</TR>
<TR style="font-size: 1px">
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top">(Address of Principal Executive Offices)
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">(Zip Code)</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt">Registrant&#146;s telephone number, including area code: <B>(858)&nbsp;312-8000</B></DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><DIV align="center"><DIV style="FONT-size: 3pt; margin-top: 16pt; width: 26%; border-top: 1px solid #000000">&nbsp;</DIV></DIV></DIV>

<DIV align="center" style="font-size: 10pt">(Former name or former address if changed since last report.)</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions:
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><FONT style="font-family: Wingdings">&#111;</FONT></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425)</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><FONT style="font-family: Wingdings">&#111;</FONT></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR 240.14a-12)</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><FONT style="font-family: Wingdings">&#111;</FONT></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Pre-commencement communications pursuant to Rule&nbsp;14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><FONT style="font-family: Wingdings">&#111;</FONT></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Pre-commencement communications pursuant to Rule&nbsp;13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))</TD>
</TR>

</TABLE>
</DIV>

<DIV style="width: 100%; border-bottom: 1pt solid black; margin-top: 10pt; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>





<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<!-- TOC -->
<A name="toc"><DIV align="CENTER" style="page-break-before:always"><U><B>TABLE OF CONTENTS</B></U></DIV></A>

<P><CENTER>
<TABLE border="0" width="90%" cellpadding="0" cellspacing="0">
<TR>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="76%"></TD>
</TR>
<TR><TD colspan="9"><A HREF="#000">Item&nbsp;2.02 Results of Operations and Financial Condition</A></TD></TR>
<TR><TD colspan="9"><A HREF="#001">Item&nbsp;8.01. Other Events</A></TD></TR>
<TR><TD colspan="9"><A HREF="#002">Item&nbsp;9.01. Financial Statements and Exhibits</A></TD></TR>
<TR><TD colspan="9"><A HREF="#003">SIGNATURES</A></TD></TR>
<TR><TD colspan="9"><A HREF="a58426exv99w1.htm">EX-99.1</A></TD></TR>
<TR><TD colspan="9"><A HREF="a58426exv99w2.htm">EX-99.2</A></TD></TR>
</TABLE>
</CENTER>
<!-- /TOC -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>






<!-- link1 "Item&nbsp;2.02 Results of Operations and Financial Condition" -->
<DIV align="left"><A NAME="000"></A></DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Item&nbsp;2.02 Results of Operations and Financial Condition</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On January&nbsp;19, 2011, Lifevantage Corporation (the &#147;Company&#148;) issued a press release announcing
its preliminary unaudited second quarter fiscal 2011 operating results. The press release is
furnished as Exhibit&nbsp;99.1 hereto and shall not be deemed to be &#147;filed&#148; for purposes of Section&nbsp;18
of the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;), or otherwise subject to
the liabilities of that section, nor shall it be deemed incorporated by reference in any filing
under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general
incorporation language in such filing.
</DIV>
<!-- link1 "Item&nbsp;8.01. Other Events" -->
<DIV align="left"><A NAME="001"></A></DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Item&nbsp;8.01. Other Events</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On January&nbsp;21, 2011, Lifevantage Corporation issued a press release announcing that its Board
of Directors and President and Chief Executive Officer, David Brown, have agreed that Mr.&nbsp;Brown
will focus all his efforts on the Company&#146;s network marketing sales channel. In his new role,
he will retain the title CEO and President of the Company&#146;s network marketing operations. The
Board of Directors intends immediately to initiate a search for a successor to assume Mr.&nbsp;Brown&#146;s
role as the Company&#146;s President and Chief Executive Officer. Mr.&nbsp;Brown will continue to serve in
this capacity until a successor is named and will continue to serve on the Board of Directors. A
copy of the press release announcing this news is attached as Exhibit&nbsp;99.2 and incorporated by
reference herein.
</DIV>
<!-- link1 "Item&nbsp;9.01. Financial Statements and Exhibits" -->
<DIV align="left"><A NAME="002"></A></DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Item&nbsp;9.01. Financial Statements and Exhibits</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;Exhibits
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="5%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="93%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left" style="border-bottom: 1px solid #000000"><B>Exhibit Number</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left" style="border-bottom: 1px solid #000000"><B>Description</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">99.1
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Press release issued on January&nbsp;19, 2011 announcing
preliminary unaudited second quarter fiscal 2011 financial
results.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">99.2
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Press release issued on January&nbsp;21, 2011.</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->-2-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<!-- link1 "SIGNATURES" -->
<DIV align="left"><A NAME="003"></A></DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>SIGNATURES</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
</DIV>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">Dated: January 21, 2011      &nbsp;</TD>
    <TD colspan="3" align="left"><B>Lifevantage Corporation</B><BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ Carrie E. Carlander
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left">Carrie E. Carlander&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left">Chief Financial Officer, Secretary &#038; Treasurer&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>


<P align="center" style="font-size: 10pt"><!-- Folio -->-3-<!-- /Folio -->
</DIV>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a58426exv99w1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML>
<HEAD>
<TITLE>exv99w1</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>Exhibit&nbsp;99.1</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><IMG src="a58426a5842600.gif" alt="(LIFEVANTAGE LOGO)">
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>LIFEVANTAGE ANNOUNCES PRELIMINARY UNAUDITED SECOND QUARTER 2011 RESULTS</B>
</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>Company Anticipates Record Operating Profit on Highest Quarterly Net Revenue to Date</B>
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>San
Diego</B>, <B>CA, January&nbsp;19, 2011</B>, <U>LifeVantage Corporation (OTCBB: LFVN)</U>, the
maker of science-based solutions to oxidative stress, announced preliminary unaudited net revenue
for its second fiscal quarter of 2011. The Company anticipates net revenue of approximately $7.4
million for the three month period ended December&nbsp;31, 2010. This represents an increase of
approximately $1.0&nbsp;million or 15% over net revenue of $6.4&nbsp;million for the three month period ended
September&nbsp;30, 2010. This is also an approximate $4.9&nbsp;million or 196% increase in net revenue over
the $2.5&nbsp;million net revenue reported for the same quarter last year.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Along with recording net revenue of approximately $7.4&nbsp;million, the Company also anticipates
reporting operating income of at least $500,000 in the second fiscal quarter 2011. Operating
income of $500,000 would generate nearly a 7% operating profit margin for the quarter, compared to
an operating loss of $2.7&nbsp;million or &#060;109%&#062; in the same quarter last year.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&#147;We are pleased to announce that we are exceeding our second quarter guidance and we
anticipate reporting our highest quarterly net revenue and operating profit to date,&#148; stated David
W. Brown, President &#038; Chief Executive Officer of LifeVantage. Carrie McQueen, Chief Financial
Officer commented, &#147;After giving second quarter guidance for a 10% improvement in net revenue, we
are very pleased to be exceeding our estimates. Additionally, we have achieved growth while
maintaining conservative spending in operations. We are proud to report our 8<SUP style="FONT-size: 85%; vertical-align: text-top">th</SUP>
consecutive quarter of net revenue growth, our 6<SUP style="FONT-size: 85%; vertical-align: text-top">th</SUP> consecutive quarter of improvement in
operating income or loss, and our 2<SUP style="FONT-size: 85%; vertical-align: text-top">nd</SUP> consecutive quarter of operating income. We remain
focused on achieving sequential growth in future quarters.&#148;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>About LifeVantage Corporation</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">LifeVantage Corporation is a publicly traded (OTCBB: LFVN), science-based, nutraceutical company
dedicated to helping people reach their health and wellness goals while creating business
opportunities. Founded in 2003 and based in San Diego, CA, LifeVantage currently offers two
anti-aging and wellness products: Protandim<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP>, a dietary supplement that combats oxidative stress,
and LifeVantage TrueScience&#153; Anti-Aging Cream, a scientifically-based skin care product. For more
information, visit <U>www.LifeVantage.com.</U>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Forward Looking Statements</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">This document contains forward-looking statements made pursuant to the safe harbor provisions of
the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified
by words such as &#145;believes,&#146; &#145;anticipates,&#146; &#145;intends,&#146; &#145;plans,&#146; &#145;seeks&#146; and similar references to
the future. Examples of forward-looking statements include, but are not limited to, statements we
make regarding our anticipated results of operations and future growth. Such forward-looking
statements are not guarantees of performance and the Company&#146;s actual results could differ
materially from those contained in such statements. These forward-looking statements are based on
the Company&#146;s current expectations and beliefs concerning future events affecting the Company and
involve known and unknown risks and uncertainties that may cause the Company&#146;s actual results or
outcomes to be materially different from those anticipated and discussed herein. These risks and
uncertainties include, among others, the risk factors contained in the Company&#146;s Annual Report on
Form 10-K and its Quarterly Report on Form 10-Q under the caption &#147;Risk Factors&#148;, and in other
documents filed by the Company from time to time with the Securities and Exchange Commission. The
Company cautions investors not to place undue reliance on the forward-looking statements contained
in this document. All forward-looking statements are based on information available to the Company
on the date hereof, and the Company undertakes no obligation to revise or update these
forward-looking statements to reflect events or circumstances after the date of this document,
except as required by law.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>Investor Relations Contact:</B><BR>
Ioana C. Hone<BR>
(858)&nbsp;312-8000 Ext. 4

</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>###</B>
</DIV>




<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>a58426exv99w2.htm
<DESCRIPTION>EX-99.2
<TEXT>
<HTML>
<HEAD>
<TITLE>exv99w2</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>Exhibit&nbsp;99.2</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><IMG src="a58426a5842600.gif" alt="(LIFEVANTAGE LOGO)">
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>LIFEVANTAGE CEO TO FOCUS EXCLUSIVELY ON RAPIDLY GROWING NETWORK MARKETING CHANNEL</B>
</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>Brown Makes Announcement at Largest Ever Gathering of Company Distributors After Company<BR>
Reports Anticipated Record Net Revenue and Profitability</B>
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>San Diego</B>, <B>CA, January&nbsp;21, 2011</B><U>, LifeVantage Corporation (OTCBB: LFVN)</U>, the
maker of science-based solutions to oxidative stress, announced that the Board of Directors and CEO
David Brown have agreed to focus all of his efforts on continuing the rapid expansion of the
Company&#146;s network marketing channel. Brown made the announcement before over 1,000 enthusiastic
distributors gathered at the Company&#146;s Elite Academy in San Diego. He will work with a search
committee to recommend a successor to assume corporate CEO and President responsibilities while
Brown retains the title of CEO and President of the network marketing operations. &#147;Given the
tremendous growth and momentum we have generated and the continued opportunity before us, I
believe, as does the Board, that I can bring more value to shareholders by focusing solely on
continued revenue and growth,&#148; Brown said. Brown will continue to serve as corporate CEO and
President until a successor is named and will continue to occupy a position on the Board.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">LifeVantage recently announced that it anticipates reporting its highest net revenue to date of
approximately $7.4&nbsp;million for the three month period ended December&nbsp;31, 2010, an increase of
approximately $1.0&nbsp;million or 15% over net revenue of $6.4&nbsp;million reported in the previous three
month period ended September&nbsp;30, 2010, and an approximate $4.9&nbsp;million or 196% increase in net
revenue over the $2.5&nbsp;million net revenue reported for the same quarter last year.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Along with recording net revenue of $7.4&nbsp;million, the Company also anticipates operating income of
at least $500,000 in the second fiscal quarter 2011. Operating income of $500,000 would generate
nearly a 7% operating profit margin, compared to an operating loss of $2.7M for the same quarter
last year.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&#147;We are pleased to announce that we are exceeding our previous guidance and anticipate
reporting our highest quarterly net revenue to date,&#148; stated Brown. &#147;&#147;These results reflect the
continued growth we have seen from both the U.S. and Japanese markets. We&#146;d like to thank all of
our distributors, customers and employees responsible for these record results.&#148;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>About LifeVantage Corporation</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">LifeVantage Corporation is a publicly traded (OTCBB:<U>LFVN.OB</U> &#151; <U>News</U>), science-based,
nutraceutical company dedicated to helping people reach their health and wellness goals while
creating business opportunities. Founded in 2003 and based in San Diego, CA, LifeVantage currently
offers two anti-aging and wellness products: Protandim<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP>, a dietary supplement that combats
oxidative stress, and LifeVantage TrueScience&#153; Anti-Aging Cream, a scientifically-based skin care
product. For more information, visit <U>www.LifeVantage.com.</U>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Forward Looking Statements</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">This document contains forward-looking statements made pursuant to the safe harbor provisions of
the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified
by words such as &#145;believes,&#146; &#145;anticipates,&#146; &#145;intends,&#146; &#145;expects,&#146; &#145;plans,&#146; &#145;seeks&#146; and similar
references to the future. Examples of forward-looking statements include, but are not limited to,
statements we make regarding our plans with respect to the hiring of a new Chief Executive Officer,
management roles and responsibilities, anticipated results of operations and future growth. Such
forward-looking statements are not guarantees of performance and the Company&#146;s actual results could
differ materially from those contained in such statements. These forward-looking statements are
based on the Company&#146;s current expectations and beliefs concerning future events affecting the
Company and involve known and unknown risks and uncertainties that may cause the Company&#146;s actual
results or outcomes to be materially different from those anticipated and discussed herein. These
risks and uncertainties include, among others, the risk factors contained in the Company&#146;s Annual
Report on Form 10-K and its Quarterly Report on Form 10-Q under the caption &#147;Risk Factors,&#148; and in
other documents filed by the Company from time to time with the Securities and Exchange Commission.
The Company cautions investors not to place undue reliance on the forward-looking statements
contained in this document. All forward-looking statements are based on information available to
the Company on the date hereof, and the Company undertakes no obligation to revise or update these
forward-looking statements to reflect events or circumstances after the date of this document,
except as required by law.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>Investor Relations Contact:</B><BR>
Ioana C. Hone<BR>
(858)&nbsp;312-8000 Ext. 4
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>###</B>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>




</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>a58426a5842600.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 a58426a5842600.gif
M1TE&.#EAT@`M`.8``*VMK<+"PLS,S.[N[H&!@24E)<3$Q-O;VQH:&AX>'L[.
MSM'1T<G)R1P<'.3DY-;6UKZ^OIB8F,#`P**BHIZ>GL;&QM+2TJJJJKJZNJ"@
MH+2TM+:VMIR<G*2DI,C(R"HJ*M34U)J:FKBXN*:FIDI*2KR\O)*2DHJ*BHB(
MB&!@8(R,C"`@(#(R,DA(2#P\/$!`0#`P,#HZ.EQ<7&YN;JBHJ#@X.$9&1E!0
M4"PL+$U-37AX>+*RLK"PL#4U-5965C8V-EE963X^/G%Q<69F9GM[>W)R<DY.
M3I65E7Y^?E145'1T='9V=E)24I:6EEY>7FIJ:GQ\?&1D9(2$A"(B(D)"0I"0
MD&)B8FAH:%I:6BXN+FQL;(Z.CB@H*(:&AD1$1!86%O[^_OW]_?GY^?S\_.+B
MXOO[^_KZ^O?W]_CX^.'AX?/S\_;V]O7U]?'Q\?3T]./CX_#P\-G9V>GIZ=_?
MW_+R\MS<W-[>WNOKZ^SL[.?GY^KJZN#@X.;FYNWM[=W=W?___R'Y!```````
M+`````#2`"T```?_@'^"@X2%AH>(B8J+C(V.CY"1DI.4E9:7F)F:FYR=D&</
M'4HI/DD^42=TGJNLK:ZOA!956"Q3";<%)'*PO(YB9[W!K'0A-@4)#;<-""QO
MPL^$8&@"`M#6F`).*U\("2O*,&37SV%S6DKCZ9(</=TK"`@KWSU\ZKUF`3TO
M]OR+<$7'$B#XL$0#`!4G@/5S)28`CA@+(Q;:D^);@@)`!`S0X^!-&(FLQ$#(
M`A&D1`L^;"7H@62-R5=F#+"H\?+2QS)EQ(!Y=`;G'S0[_RA(HC+&B:"*V/3I
M<T<.G3'6P""]9*;"S*G0I#;"NDB`!0\&*ICQ!:%"!0L+%"Y(8K&'CCAV_^S4
ML6,(3AP-'"(<.7)A@9ZQA<;`*?.H#!TUA="XZ?AFCH.G6J.A@4.(SAL_<1[,
MN8/&D!@),^_0@0-'C6FHA<"<T4.&3!HR@QN9Z9,F3IP#9/H$#:.:#N%#8=KX
MF6,[CYM%-DB0L)%"#U=#91;<:-&"1!4]@M9:+/`BQ1`K*8KT&>3F0`@95'!D
M8?'#A0\4`=I$>\`!PGA&:Q9DN##@3YD[!V@P0A%"%#$#$10P@`=@@H0Q``81
MN`$&&W5,H(,33-SPQ`D8O"$&(2+UP$($%$P00@84=!!'9W\(YD<%`)Q0Q!-/
M*!%!"6D@AH@8>01P1!$R)`&$$DT8<(=.?6`PP?\!'Q%2AAP"1/!$"C?<0,0$
M#[#1I"'P",3"',\EID$!\"#PA`."#'6+/`5,T>8408@CB`%+O/!-,BM,(4\/
M46R`U!@9O)`#!(V0<4(+4=@!A@,1I.`""P5P\<&D+#!!@9R"3#-$#V6$P4`*
M,7Q@T10?D&!"&B`&``,"/>#``@RODD`#'H+`H8$0+?SP00%M%O`!%5!($"89
M3?@``Q=3N(G##S9$D,88<SQ!P@X*#2+'!#*PL$*;*W#!P@P,5%N(/%,,A*DB
M:(@@$#)`["&(`#=XH^<R`B'P`W9A\$#%._'4VPTR";Q0!65_@!$`%5-$P8A(
M)"0@!1IOI'`+#B\,H8/_#EHD\8.;0)2`&AH&4('`&R=0P0450E0Q@0E#N#`%
M%U8\,$A5VK9@@\TMO`#$#OVU(86H7+@W`Q)(R.!"FRY<(.X?;NR0`@Y<O.`$
M$B9L,807'R30`@1V`%%`!RX-8H`3O+Z`1`@7F&#L"C"@D,:6@]PBT`?G)G*&
M"/0VX(.[?S`0KS*WZ)F`"V^@L8$/!2S3@*\LL/"!+0TLW@(&@[2A0P$N?*B(
M`T<XS@`8><Q@0Q$:6$"&`WR\<=<2K0X1@"!G!-#""ASD$`,4`:2AQP!WD`&!
M$(V;X,P?,?7@@@`')'\`7'!`A08%/LQ`@0!VO)$''WLPH,(+!?A@P'&"B+$!
M_Q8/05'!''G<H<<<%630`@M`J'##!Q=H+M0,,-10A`1YX,&['P&0P11<8((\
M&`)@YFH$&DH`L`2TZUU_2\`4>H"S%@Q!#@,H0M;@`8,;Z*`*)M#!#7``,"X@
M`4T%NT`//E`!^QG"4T_`@1'&PX827$`CJ!'$&`9@@"?HPP0N<0,&;)``'[S`
M"@Q00Y-XTP8,#`$&,O#3'QH"`Q<LC1!A6,`%`D`&%@T"#7&0@@M@(`44_D$`
M.OA!#9"@@+`UB`UO<-H+;A`JI0G"`=N+@0X\H(I!@&$-(R#!!X```3<*HH$X
MJ-N.)""09&"!;P)@@D6RD`(*E(@"&NB#`5[0#004X/\*'5B`'.2P`.AE[1:3
M&T0<<E"`$Q#L$&RX@`UZ@((FY<1N/*#%$^K`M`W8H`%<2`$`7,@;,`Q@!"VH
MP0E<(A(8E"018FB#"PMA`1U,P0@6V`D=JO""&LQ``8D`@P:,%:D)L(%X&[@!
M"X;``+A9ZPA!8`$*ZB:W!"2R$9^I5P)D`$E)WJ(&*D`*&/:@`RYX`P$V@`"#
M_M`&#LSN%A]0`6K<(`0<R,`..2R$`U#``A(PX!%R4$%'*1>[''AR!'V,QD[B
MH`0<:,$9#:G!,RDQ!H?```.=40`0/B`#RBD"#/"4(`40(P<"P"`'`%`$'Y[P
M@214H!!R:P#=\,G(!GQ#!JC_$@H3BF*"0BB@!@G@`CQ,D%%!S($(IUQ!"EXI
M@A?TX`(Z,H0!?(`#(ISS$2*P00Q&0#P!M``!+?!#F/XP@`RPX`8?;0@+9DH)
M-;#2!'?X`P=^``,3]&<1<D#"RSIP3@'XX`-(N&LB*!"#`M``JLJ8ZL*J>M6L
M*F"K_ZQ"(33`!:NNX`4&0(0(;E`F&[Q.$&\0P@IF8$!#G"$"+J#"!"*A@"BP
M0`I];9@.+HN(,&#`!3;0P!0#L-A,I.`#.IC#'XB`@QSXE!$`J`$7,J"&,FC`
M!2W8`2-TR@4"O/(/];SG:I'1VC3!-@$`18H95%"F`J1`9H08`U08,`2YU8`#
M@SC#_PX00`4!+/2.3U@G.`VA.@AL0`,:P(`'_`"'"CB7"'^(W2\O8$A#@$$`
M-@C"<A7+6$1,:`X!V(`(-"`"`UB`#W*(P@>B\(`V?/<)"W"$`G+`A:'"@0,P
M&`*"%:$&'<`@!>>RB#T5>8A\6G6?KOWO#TZP)8IV<@HWX$L&1D"##G1@!!>H
M0A+DA@,"^%$../@`!6A5"+\&P03R&8080J&$(=P@!\K)`1">`(4BV(`%=F8#
M!/XJ@-\DP@(Y<`$%MMM=192#!R>8`1-(@&@AI4`)4K#!!YYP@#O0%0IT:40:
M9/`!<_(!!3@0`@AXAX<VX.'7P/XU'XC`@AS$@1!:UN\B1/_"7S#[5R6TS"$<
M)/:.%?P@!TS(096TG81L@[4;7!!"(1`W@P=,!0T\8($/""4(,-`!`@2X00UJ
MX((7O"`(+IBW"UR0!1ATX0^2-ND!RFH($-S`!1`6@TP8.Y4S+,`$3NAF#8)`
MA1=XP04]J($-<#`%+1Q`#B.4PO`8(0<K?`!L:4`"%[`0@0YD8`(TF(#,9SYS
M)WS@!2!`-IVY[!D(-!NK_FW+"2P]`!_44\MEZD;D],F%&13B"+_2@+@<8%0D
MU$,0:PB`$W```Q(,`04FB$`$5*`#*J6GSJHQP`T:8`=W&L("!X=P3#H]B"V%
MX0!+B`$,@B`#)#2!`R%H`A(,/;__!@PA#GF8'P%X;@@'6`$'8"/H%&#P`BKL
MV]Z8S_S[5A`#"^A\8HP'D<^_#'2M6F3,EJ8#%KITBZ1_HY/_`K?3"7$`K)W@
MZG-BP@M..X@ZS&`%'YB!`=K@ABU!3`$4,`(.=#"&,QB`!&QW.S4S+?>%)P*0
ME)5!!@Y@B`$(``,^X,(5XB"')'"A",=NQ`$^.P$WI($(;OK`L5XVJ?K;_P,X
MN$'Z#ZD,92O"R[=0>J]E$350!9:V!EJ`0!V5;2V0`SE0'<I!'<KA`T=@""K0
M0;DE"')P`BR@!+P4/AP(`Q'P(6%R5BQ`!&$0.R+S-HNP`"2@:9Q68X,@`4"`
M`S-0#8I`_P`?<&!G,`-<<`/LQ@@[X`*UI@8/4`19(`0*<`9CP`9TL`90N`:F
M81IM0`<#L`93$57^!TU5%8!A9A$Q8`*6A@8Z@$"NXP=U<`!UD(9KJ#QKZ`>1
MU6<OP`(C4'Q_L`!7D`4<X$4#8'(WP`>#]0<'H`3/!09BP``MD``LJ`A^-F/<
M)8/$@UQ>P`/@DP@%=7A@@`)94`-#Q0AJL`63,@)LH`<J\`%0X!Q2D8JJ*!6\
MP1M0I3A;N",^YPT-(("PU0``Q2!E0`'OT`!?<`-)Q@C/`0=/D`4S<`!@4`8`
M0`54\%2#\`8M`%K21P@@\`0P8&=HX`$YT`"+F`@"0`(OL%PT`_^)/I,%,K``
M@?@',U``1/8'&]`"3;=ABH`!0`!\'>`&;I`!5R:/DM!Z#1"+AX`&&/`OM9A5
M\')Z0^='$/`!W?`%='AA[;88NU!=31`#)&``8"`'*'!E9O0'<_`",`!A8Q`F
M8V``-0@%JA$`T$<&TS@(WPB#"I<_B(`'.K!JL98(9B!`[3@',X`#+7`$N'<(
M::`#-3`%.#`!:F`&[T4%(V!ID6!5R8`#?A`&83`&.'&59:!@8Y""&X``R5"0
M@L``.2`/`"9;L4!$Q]``43`'904&;2``%'`!*64($.`#,4`#8E`!5O!<XD(&
M5``#FX:%B-`&'?`".``%95!#5)``++G_"`I``C$0`3\!`3)Y"'U0DS/`-S;F
MEY]T;&@P`4:0!3DP`@.`%6!@!F]P!-W4.!,@'SH%`R?$"%3));C``A70!VW0
M%*.TFWJ@!W?@!F>@`5^F-WRS%H+S`V8Y"`X@!>62`%\``U405[`#`3/P`CZ`
M`00G",/&`CK@`!3P`BVP`84@!X)D9XJ0!RC`!6TC!FL@`5Y0`(VI"`87CL3#
M`#\`B6<@!3`0!<&("&.@`;MR>()@*#V@-1?@1>&S!UKP`BX0!3:@A_V16:4B
M7XO0!@/@E'^0ELX)-9%R?_5'`A-PB(JS`J4'+_5"2PN5D=KP+RM@!%40`'-0
M!P#P!"ZP#5JC_UV(@`'@>`).P!)Q6#D^&`,&\!$7MBA(T`XX4`6G"6,($)^)
MH``MX`++50XU\`'BV2("U@0_T`--@!W`,0*\E0`'-@AD8`(D0"H^(`4;L``"
ML`6.,@4D<$,UR%D%XP'?900;,$U?=`%`D`+.&#=>^0Z04T^$&@048`8*\)5B
M*B<'^4\)20AHL`,DT"6>5$7*X0(<UTC9E0ARH`,]0$=QBJ%C,`$QD`!#H`!E
M@!0I>``F0`4LD&=(@`:'^%=.B@@N&`0=4#!M0`(%4`0W.46\P6`?X`,`$&B$
MD"0WT`,KQ&HS\P8`(`,P('\Q8&\]``-11@-Y8`<:PP.:XP83$`0\=?\!QCH(
MH9`$'V`$KR,&8H`3>/(-6D:H<J-I`AE[C_0N1E`OST5P;G`!+7`,@=IZL#<%
M,:`"(W<((U"4X;9_A)!R>>8#)H`!R&,!&Z`"*?`"2:`$,E!7AL@`#5.KA^""
M,"@()R`B0]`!!F``,1<'O\`#+_`!+8`$&B``#Q`'!G`!0Q"E4S(%8TH(;J``
M6R`#41H#+I`#7W<`2@0".5`#%R!:>U`%5/`!02`$.\``F`$!$S`$;G4#')`'
M8/``(/8`!.D.\%I/\BH!BEIZ#.!/*]$%$/D'>1`"2<`"ZZ(,7KDX5*`#%I"=
M@U`!-[`"+M`$]S4(:U`!,U`#+&`#,B`$2Z#_!3+P@B00`CPP!)#V!UDW.QYK
M"-+Q`A`V)T_#`D8`'C>0`AM0FG[0!23``NYQ!450:$E`>42``0"1`CE7"&90
M!Q@P`GH1`1<@`?L7,BX``*)E!B"@`EZPB3[P!#J@!$Z0M##@`Q%0!TT(`0@1
M`$(K4T%`;_N6O=KK`D#``V,0!S7`H"Z@`U<7!T)P;]9)`1@Z"`.P`SKP:`60
M)XSS`E%``9ZW"`-P`CF@!!4PC6;P`"=@1#6@K#T0`SGP!!3@`'9P`D"0JV*P
M`-)RN87@!X5VI7]`!QJ@!2T@(JB;`@&@!F`P!GMPM39@N!D7OO%S`&9P!$D@
M!>+EGV=P!F@`-V9P_P$_0`(2X)1CD`894`20^0.-LUA`H`,\P`=0T40G<`(!
M0`%ZP0$=$'9Y(792+,47<&QJ<`(30`%-L`%]I`8B$`$A$`(C<+^)X`<=T`6,
M"P0R,`0$,#TM60@@,`(!P&>140@#``$10``S(`1$<`(78`&=\;\\D%5N$``\
M(`?IN`8>YJ6"4`8R*@5$0`0F(`+4]0=J8`$T@`(&PL<AL`!W!0(8X,F2H`<$
M8(/<!QUY<`$GH`17\`1$\*)P8'QQ4`)<TP^Y.4I]<`9OG`EF8`:NR`MK`!2)
M$`9KX`9HH+>#4`9HL+Z'(`!,1@'WX9]BX`9)F8XU<<WJL`,H``#%E0AQ\(X$
MN?#"V#S.Y'P(<$``,1`$2@`!?%8(92``P-,#`U/.]%S/9C`!(]0#28`$'0"Q
M#_``AAP!,J"L!!`'R%S/"-T/4O$`%/`$+T`2-Q`%.M`%4C`#C8L#-2`$#*"G
M"=W1_5!,;"``)H`>++`>\V:M-9`$!"``HN71+AT18V`&5AE'.N`#0:"LB*("
(T-LBGA`(`#L_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
